The expression and activation of ERK/MAPK pathway in human esophageal cancer cell line EC9706.
While there have been more and more studies concerning mitogen-activated protein kinases (MAPKs) signaling pathways, which control many cellular complex programmes, such as cell proliferation, differentiation, cell death and embryogenesis. However, few studies are carried out about expression and activation of classical MAPKs, extracellular signal-regulated kinase1/2 (ERK1/2) in human esophageal cancer cell line. Therefore, in the present study, we investigated the expression and activation of ERK1/2 in human esophageal cancer cell line EC9706 and human normal esophageal epithelial cell line Heepic, which is as control. This study showed that ERK1/2 was transiently phosphorylated both in EC9706 and Heepic, the kinetics of which were slightly different. To further study the ERK/MAPK signaling pathway in EC9706 and Heepic cell line, U0126 a kind of specific inhibitor of MEK was used. This study showed that U0126 can block the phosphorylation of ERK1/2 in a short time, the complete inhibition concentration for EC9706 and Heepic cell line is 50 and 20 μM, respectively. Incidentally, to further investigate the different roles of ERK1 and ERK2, vector-based short hairpin interference vectors targeted on ERK1/2 was constructed. Moreover, the effective interference target sequence was screened out in a transient transfection manner. MTT experiment showed that ERK2 is more important than ERK1 in the proliferation of EC9706 cells.
Zheng
Shu-Tao
ST
Medical Research Center, the First Affiliated Hospital, Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, People's Republic of China.
Huo
Qi
Q
Tuerxun
Aerziguli
A
Ma
Wen-Jing
WJ
Lv
Guo-Dong
GD
Huang
Cong-Gai
CG
Liu
Qing
Q
Wang
Xing
X
Lin
Ren-Yong
RY
Sheyhidin
Ilyar
I
Lu
Xiao-Mei
XM
D001483:Base Sequence; D002070:Butadienes / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004938:Esophageal Neoplasms / Q000378:metabolism*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D020869:Gene Expression Profiling; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020935:MAP Kinase Signaling System; D008969:Molecular Sequence Data; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation; D015398:Signal Transduction
D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; C113580:U 0126; D048049:Extracellular Signal-Regulated MAP Kinases
J Biol Chem. 1999 Sep 10;274(37):26563-71
10473620
Leukemia. 2002 Apr;16(4):486-507
11960326
Cancer Biol Ther. 2005 Sep;4(9):961-7
16138005
Curr Opin Cell Biol. 2001 Apr;13(2):244-8
11248560
Mol Biol Rep. 2009 Feb;36(2):357-64
18046624
Mol Cell Biol. 2008 Jan;28(1):511-27
17967895
Oncogene. 2004 Jan 22;23(3):763-76
14737111
J Am Coll Surg. 2004 Mar;198(3):410-21
14992744
Br J Cancer. 2004 Aug 16;91(4):795-802
15280923
Nat Biotechnol. 2002 May;20(5):446-8
11981553
Mol Biol Rep. 2010 Jan;37(1):363-8
19757177
Cell Death Differ. 2009 Mar;16(3):368-77
18846109
Adv Cancer Res. 1998;74:49-139
9561267
Best Pract Res Clin Gastroenterol. 2007;21(6):921-45
18070696
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Mol Biol Rep. 2010 Apr;37(4):1971-7
19649725
Biochem Biophys Res Commun. 2008 Aug 8;372(4):845-9
18533112
Cell Growth Differ. 2001 Aug;12(8):397-408
11504705
Oncogene. 2008 Sep 11;27(40):5315-25
18521085
J Neurosci. 2004 Jun 9;24(23):5322-30
15190104
Stem Cells. 2004;22(1):93-9
14688395
Mol Biol Rep. 2010 Jan;37(1):197-205
19562509
Hepatology. 2007 Apr;45(4):1035-45
17393467
J Physiol. 2005 Jul 15;566(Pt 2):409-23
15890698